Friday 16 April
Eradivir is a privately held, clinical-stage biotech company pioneering a novel small molecule immune-driven approach to treat disease. Our Bispecific Antigenic immuno-Therapy (BAiT™) technology targets diseased cells, flagging them for clearance by the immune system. We are advancing a pipeline of antibody-recruiting small molecules, including our lead therapeutic EV25 for influenza and EV148 for RSV. Our team of industry veterans has a strong track record of developing and bringing drugs to market. To learn more about us, visit www.eradivir.com or follow us on Social Media @Eradivir.